KR102113431B1 - Anti-inflammatory composition containing medicinal herbs - Google Patents

Abstract

The present invention relates to an anti-inflammatory composition. In detail, the present invention relates to a powdered anti-inflammatory herbal composition comprising chicken foot extract, has excellent stability, is not only harmless to the human body, but also effectively suppresses the expression of inflammatory disease-related mediators, thereby providing excellent anti-inflammatory effects. It represents the excellent effect on the improvement and treatment of inflammatory diseases.

Description

Anti-inflammatory composition containing herbal medicine and its manufacturing method {ANTI-INFLAMMATORY COMPOSITION CONTAINING MEDICINAL HERBS}

The present invention relates to an anti-inflammatory composition that exhibits an excellent anti-inflammatory effect by suppressing the expression of inflammatory disease-related mediators, and more particularly, to a powdered anti-inflammatory herbal composition comprising chicken foot extract.

Inflammation begins as an action to defend against cell damage caused by external biological causes (bacteria, viruses, parasites), physical causes (mechanical stimulation, heat, radiation, electricity), chemical causes, etc. , Various immune cells and inflammation-inducing cytokines are involved. Specifically, inflammation is caused by the release of inflammation-inducing cytokines, vasodilation, increased capillary permeability and aggregation of macrophages into the inflammatory site, thus increasing blood flow in the affected area, edema, immune cell and antibody migration, pain , It is one of the body's defense reactions to prevent damage to biological tissues due to fever.

Arthritis, a type of disease caused by inflammation, refers to a disease in which local cartilage changes as the joint cartilage wears out. The cause of the onset is still uncertain, but it is known to have a deep relationship with aging or excessive weight. Degenerative arthritis is also called degenerative joint disease, osteoarthritis or osteoarthritis.

When arthritis progresses, the bones become hard, and excessive formation of bone, deformation of the joint, etc. may occur around the joint. According to clinical studies in the United States, degenerative arthritis is the most common inflammatory disease of the joint, and about 80% of people over 55 years of age on radiographs and almost the entire population at 75 years of age show signs of degenerative arthritis.

Since degenerative arthritis has such a high incidence, there has been much interest and research on drug treatment for arthritis patients, and there have been many efforts to develop foods or health supplements useful for arthritis in addition to therapeutic agents.

A large number of functional foods or health supplements for improving joint function known in the prior art have glucosamine components. Usually, these foods or health supplements use a drug consisting of a single component of glucosamine, but only show symptoms of suppressing effects rather than fundamental treatment or improvement. Therefore, there is an urgent need to develop a drug that can protect the joint cartilage itself or directly treat or improve the damage.

From this point of view, efforts to find an arthritis-improving agent derived from herbal medicines have been attempted in various ways, but the amount of use is limited or actual product due to digestive disorders caused by herbal medicines and poor storage stability (e.g., deterioration or decay) When applied, it was difficult to achieve a practical effect due to limitations in use.

Accordingly, the present inventor has repeatedly studied new anti-inflammatory compositions that are safe for living bodies and are highly effective in inflammatory diseases such as arthritis. As a result, by mixing the herbal ingredients combined with chicken foot extract having efficacy in improving degenerative arthritis, powdering is possible without excipients, as well as confirming that it exhibits excellent effects in suppressing the expression of inflammation-induced cytokines involved in inflammatory diseases. The invention was completed.

An object of the present invention is to provide a composition for anti-inflammatory that can be powdered chicken foot extract without excipients, thereby improving long-term storage stability.

Another object of the present invention is to provide an anti-inflammatory pharmaceutical composition excellent in the improvement and treatment of inflammatory diseases, by effectively suppressing inflammation-induced cytokines.

Another object according to the present invention is to provide an anti-inflammatory food composition and an anti-inflammatory feed composition that are excellent and safe for improving and treating inflammatory diseases that can be performed.

In order to realize the above object, the present invention provides a composition for anti-inflammatory, comprising a mixture of herbal extracts containing dandelion, safflower seeds, hyssop and brown roots in chicken foot extract and powdered extract processing by-products.

In the composition according to an embodiment of the present invention, the mixed herbal medicine may satisfy the following relationship (1).

[Relationship 1]

0.7 ≤ A + B / C + D ≤ 1.3

[In the above equation 1,

A (dandelion), B (safflower), C (wooss), and D (grass root) are the weight percent of each herbal medicine in powder form, and the weight percent of each herbal medicine is based on the total weight of the composition.]

In the composition according to an embodiment of the present invention, the composition may be an anti-inflammatory composition comprising 15 to 40% by weight of the chicken feet extract and 45 to 80% by weight of the mixed herbal medicine.

In the composition according to an embodiment of the present invention, the composition may further include one or more selected from glucosamine, glucosamine derivatives, and pharmaceutically acceptable salts thereof.

In the composition according to an embodiment of the present invention, the glucosamine derivative may be N-acetyl glucosamine.

In the composition according to an embodiment of the present invention, the composition may be formulated as a tablet or a pill.

In the composition according to an embodiment of the present invention, the composition may be a pharmaceutical composition for anti-inflammatory.

In the composition according to an embodiment of the present invention, the pharmaceutical composition for anti-inflammatory may be for improving inflammatory diseases.

In the composition according to an embodiment of the present invention, the inflammatory disease may be arthritis.

In the composition according to an embodiment of the present invention, the composition may be a food composition for anti-inflammatory.

In the composition according to an embodiment of the present invention, the composition may be an anti-inflammatory feed composition.

The composition according to the present invention is a powdered composition containing a high content of chicken foot extract, solving the problem of poor stability that is easily deteriorated or decayed in the colloidal state, which is a problem of chicken foot extract. Thus, according to the present invention, the storage stability of the chicken foot extract as well as its processability can be expanded to improve its application.

In addition, the composition according to the present invention effectively suppresses the expression of inflammation-inducing cytokines, thereby exhibiting improved anti-inflammatory and anti-inflammatory effects. In particular, in combination with a glucosamine-based compound, it is synergistic in anti-inflammatory and anti-inflammatory effects, as well as excellent in alleviating pain caused by various types of inflammatory diseases caused by various causes.

In addition, the composition according to the present invention is also excellent in safety to the human body by using a combination of herbal ingredients that are secured stability.

1 is a graph quantifying the expression level of interleukin-1 beta (IL-1β) according to the treatment of Example 1 in the present invention.
2 is a graph quantifying the expression level of interleukin-6 (IL-6) according to the treatment of Example 1 in the present invention.
3 is a graph quantifying the expression level of tumor necrosis factor-alpha (TNF-α).

The anti-inflammatory composition according to the present invention will be described in detail below, but unless there are other definitions in the technical terms and scientific terms used at this time, those skilled in the art to which this invention belongs have the meanings commonly understood, In the following description, descriptions of well-known functions and configurations that may unnecessarily obscure the subject matter of the present invention are omitted.

As used herein, the term "inflammation" refers to a phenomenon that occurs when a cell or tissue is damaged by any cause for a series of defense purposes to minimize its reaction and restore the damaged area to its original state. It is a collective term that causes lymphatic disorders, body fluid reactions, and cellular reactions, resulting in pain, swelling, redness, and fever, causing dysfunction.

As used herein, the term “inflammatory disease” refers to cartilage-related inflammatory diseases, specifically interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF). -α) refers to diseases caused by inflammation-causing cytokines, and collectively refers to diseases caused by cartilage, cartilage tissue, joint tissue (synovial membrane, articular cell, subchondral bone, etc.) being injured by an inflammatory reaction. Examples include, but are not limited to, osteoarthritis, degenerative arthritis, rheumatoid arthritis, Lyme arthritis, calcifying myositis, humeral osteoarthritis, plantar fasciitis, exfoliative osteochondritis, arthritis after meniscal plaque injury, and heresy osteoarthritis.

As used herein, the term “inflammatory induction cytokine” continuously increases expression by an inflammatory response, and improves or treats inflammatory diseases by inhibiting its expression. At this time, improving or treating an inflammatory disease refers to all actions that improve or benefit the inflammatory disease by the composition according to the present invention.

As used herein, the term “chicken feet extract” refers to a collagen extract extracted from clean and sterilized chicken feet. Collagen is a fibrous protein composed of amino acids. It is mainly present in the membranes, cartilage, teeth, hair, muscles, bones and skin surrounding the organs and strengthens joints. Chicken feet have long been known to have an effect on arthritis, especially degenerative arthritis, and recently known to have an effect on skin beauty and blood pressure enhancement may also be said to be a bioactive effect of these ingredients.

As used herein, the term “dandelion” is an asteraceae perennial plant, Dandelion (Taraxacum nonogolicum H. Mazz), acid dandelion (Taraxacum ohwianum Kitamura), white dandelion (Taraxacum coreanum Nakai), western dandelion (Taraxcum officinale Weber), etc. It is a herbal medicine obtained from. Dandelion is known to be used for swelling caused by heat, mastitis, sore throat, acute hepatitis, strengthen immune function, and protect liver function and has diuretic effect. Dandelion contains 17 species, excluding cystine, among all the constituent amino acids, and contains all 8 essential amino acids. In addition, K, Ca and other minerals are very rich, and the content of Mg, Mn, and Fe is also high.

As used herein, the term "safflower" is a medicinal herb that corresponds to the seed of safflower, and contains a large amount of fat. Safflower is known to be effective in circulatory diseases such as arteriosclerosis, hyperlipidemia and hypertension, and bone diseases such as osteoporosis and arthritis.

As used herein, the term “wooseu” is a perennial herbaceous plant belonging to the family Viraceae, and is sometimes referred to as a horseshoe knee because the shape of a node on the plant stem is similar to that of a cow. Woosul is a herbal medicine that corresponds to the root of the knee, and contains saponin and a large amount of calcium as active ingredients, and has the effects of knee disease (arthritis, rheumatoid arthritis, inflammation caused by bruising), high blood pressure, and diuretic action. It is known.

The term “brown root” used in this specification is a herbal medicine corresponding to the skin of the root of the root, and contains a lot of female hormones (eg, isoflavones, etc.) involved in the process of biosynthesizing collagen. This is about 600 times that of pomegranate extract. The thirst is sweating, it lowers the heat, treats high fever and headache, quenches thirst, is used for indigestion, headache, anemia, dysentery, abdominal pain, alcohol poisoning, cold, vomiting, and lowering of women and helps digestion.

Chicken foot extract, which is known to have efficacy for arthritis, is not easy to store for a long time due to its low stability in liquid or colloidal state. In order to solve this problem, methods for powdering using an excipient or storage after sterilization after extraction have been proposed. However, even in the case of sterilization, the storage stability was only about 6 months, and the method of pulverizing using an excipient was also unable to completely powder the chicken feet extract, and the storage stability could not be greatly improved.

In view of these problems, the present inventors have conducted studies to find a combination of herbal medicines that help perfect powdering of chicken foot extract having excellent efficacy in inflammatory diseases such as arthritis. Thus, surprisingly, as a result of adding the mixed herbal medicine containing dandelion, safflower seed, hyssop and brown root to the chicken foot extract in powder form, it was confirmed that a powdered extract processing by-product containing the chicken foot extract can be obtained.

Furthermore, it was confirmed that the obtained extract processing by-products effectively suppressed the expression of inflammation-induced cytokines and showed excellent effects on inflammatory diseases induced therefrom.

Specifically, the composition according to an embodiment of the present invention may include a mixture of herbal extracts containing dandelion, safflower seeds, hyssop and brown roots in chicken foot extract and powdered extraction processing by-products.

The composition according to an embodiment of the present invention may provide a by-product of extraction processing powdered into particles of a suitable size according to the above-mentioned mixed herbal medicine.

In the composition according to an embodiment of the present invention, each medicinal herb may be in the form of a edible pre-treated powder after drying and crushing the leaves, flowers, stems, branches, roots, outposts or seeds of plants. In addition, each herbal medicine is powdered by condensing the extracted extract according to a conventional method known in the art by adding an extraction solvent to one or more selected from leaves, flowers, stems, branches, roots, outposts and fruits of plants. It may be. That is, in the composition according to the present invention, dandelion, safflower seeds, hyssop and brown root may be a dried product obtained from each herbal medicine or a concentrate of all extracts or fractions extracted by an extraction solvent.

For example, the dandelion and hyssop may be in the form of a powder pretreated to be edible after drying and crushing the outpost of each plant.

For example, the safflower seed may be in the form of a powder pretreated to be edible after drying and grinding the safflower seed.

As an example, the root of the plant may be in the form of a powder pretreated to be edible after drying and crushing the roots of the plant.

For example, the particle size of the dandelion, safflower seed, hyssop and brown root is not limited, but may have an average particle diameter of 100 to 5,000 nm, specifically 200 to 3,000 nm, more specifically 300 to 1,500 nm It is good to have a particle size.

In the composition according to an embodiment of the present invention, the mixed herbal medicine is easily powdered as it is added to satisfy the following relational expression 1.

[Relationship 1]

0.7 ≤ A + B / C + D ≤ 1.3

[In the above equation 1,

A (dandelion), B (safflower), C (wooss), and D (grass root) are the weight percent of each herbal medicine in powder form, and the weight percent of each herbal medicine is based on the total weight of the composition.]

In the composition according to an embodiment of the present invention, the value of A + B / C + D is preferably 0.75 to 1.3, and more specifically 0.85 to 1.2.

When the above range is satisfied, it is possible to provide a by-product of high-quality powdered extraction processing, thereby improving storage stability. Thus, it is possible to effectively suppress the deterioration or decay of chicken foot extract. However, in the case of a composition that does not satisfy the above range, the desired storage stability may be deteriorated in a rather damp gel form, but it has the aspect that it is possible to formulate without additional binder when formulated as a tablet or a pill.

The composition, based on the total weight of the composition, may include 15 to 40% by weight of chicken feet extract and 45 to 80% by weight of a mixed herbal medicine containing dandelion, safflower seeds, hyssop and brown root. Specifically, the composition may include 15 to 35% by weight of chicken foot extract and 50 to 80% by weight of a mixed herbal medicine containing dandelion, safflower seed, hyssop and brown root, and more specifically, the composition is 20 to 35% by weight of chicken foot extract % And may contain 55 to 75% by weight of the mixed medicinal herbs, including dandelion, safflower seed, hyssop and brown root.

In addition, the composition may provide a composition comprising a more stable powdery extraction processing by-products as input to satisfy relational expression 1 at the above-described composition ratio.

The composition according to an embodiment of the present invention may be a composition for anti-inflammatory.

The composition according to an embodiment of the present invention shows excellent anti-inflammatory effect, that is, inflammation-inducing cytokine expression suppression effect. Accordingly, according to the present invention, it is possible to more stably supply a composition having an excellent anti-inflammatory effect, as well as exert an excellent effect on an inflammatory disease caused by expression of an inflammation-inducing cytokine.

In addition, the composition according to an embodiment of the present invention is secured for long-term storage stability, and is effective in oral administration therapeutics, foods, or health supplements that require continuous supply for effect expression.

Specifically, the composition according to an embodiment of the present invention effectively inhibits the expression levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Thus, the composition according to the present invention exerts an excellent effect on inflammatory diseases, that is, arthritis.

The composition according to an embodiment of the present invention may further include a glucosamine-based compound selected from glucosamine, glucosamine derivatives and pharmaceutically acceptable salts thereof. In this case, the glucosamine derivative may be N-acetyl glucosamine or the like.

The composition may include a glucosamine-based compound in an amount of 1 to 20% by weight, specifically 5 to 20% by weight, and more specifically 5 to 15% by weight, based on the total weight of the composition.

For example, the composition may include chicken foot extract 25% by weight, dandelion 15% by weight, safflower seed 20% by weight, hyssop 15% by weight, 15% by weight, and N-acetyl glucosamine 10% by weight.

  For example, the composition may include chicken foot extract 25% by weight, dandelion 15% by weight, safflower seed 25% by weight, hyssop 15% by weight, brown root 20% by weight, and N-acetyl glucosamine 10% by weight.

The composition according to an embodiment of the present invention, by adding a glucosamine-based compound, shows surprisingly improved anti-inflammatory effect as well as relief of pain caused by inflammatory diseases caused by various causes.

Hereinafter, a specific aspect of the composition according to an embodiment of the present invention is examined.

The composition according to an embodiment of the present invention may be a pharmaceutical composition for anti-inflammatory.

The anti-inflammatory pharmaceutical composition is not only safe for the living body, but does not cause side effects with a combination of herbal ingredients, and effectively modifies or treats inflammatory diseases by controlling the expression of inflammatory disease-related mediators.

The pharmaceutical composition for anti-inflammatory according to an embodiment of the present invention specifically, effectively expresses the expression levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). By suppressing, it gives an improved anti-inflammatory effect. At this time, the present invention can provide a synergistic effect on the anti-inflammatory effect as well as a pain relief effect by adding a glucosamine-based compound as described above.

In addition, by confirming that the pharmaceutical composition for anti-inflammatory according to an embodiment of the present invention does not exhibit toxicity at a concentration in a range that does not induce cell proliferation, it was found that they are very safe.

That is, the pharmaceutical composition for anti-inflammatory according to an embodiment of the present invention is administered orally, effectively suppressing inflammation-inducing cytokine expression, exhibiting excellent anti-inflammatory effect, and can be developed in various forms of formulation as storage stability is secured. It is expected. At this time, a preferred example of the formulation may include powders, tablets or pills.

Examples of inflammatory diseases include osteoarthritis, degenerative arthritis, rheumatoid arthritis, Lyme arthritis, calcifying myositis, humeral osteoarthritis, plantar fasciitis, exfoliative osteochondritis, arthritis after a meniscal chondrocyte injury, and heterophasic osteochondritis. The pharmaceutical composition for anti-inflammatory according to the present invention is excellent in improving or treating arthritis such as osteoarthritis, degenerative arthritis, rheumatoid arthritis.

The composition according to an embodiment of the present invention may be formulated as a pharmaceutical composition for anti-inflammatory tablets or pills.

For example, the pharmaceutical composition for anti-inflammatory according to the present invention may be formulated as a pill containing 35 to 50% by weight of the extract processing by-product according to the present invention, based on the total weight of the composition.

For example, the pharmaceutical composition for anti-inflammatory according to the present invention may be formulated as a tablet containing 70 to 95% by weight of the extract by-product according to the present invention, based on the total weight of the composition.

In addition, it may further include a pharmaceutically acceptable carrier for the desired formulation. For example, pharmaceutically acceptable carriers for oral administration include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, flavors, vitamins, minerals (e.g. dietary sulfur, etc.) And mixtures of one or more of these. At this time, the carrier may be included in the remaining amount excluding the by-product of the extraction process based on the total weight of the pharmaceutical composition for anti-inflammatory according to the present invention.

The composition according to an embodiment of the present invention may be a food composition for anti-inflammatory.

* At this time, the food composition for anti-inflammatory can be formulated as a solid dosage form of various foods and health supplements, for example, powder, pills (granules), tablets, and the like.

For example, the food composition for anti-inflammatory according to the present invention may be formulated as a pill containing 35 to 50% by weight of the extract by-product according to the present invention, based on the total weight of the composition.

For example, the food composition for anti-inflammatory according to the present invention may be formulated into tablets containing 70 to 95% by weight of the extract by-product according to the present invention, based on the total weight of the composition.

In addition, it may further include components commonly used in the art for the desired formulation. Examples include nutrients, vitamins, minerals (electrolytes), flavors, colorants, neutralizers (cheese, chocolate, etc.), organic acids, thickeners, pH adjusting agents, stabilizers, preservatives, minerals (e.g. dietary sulfur, etc.) And mixtures of one or more of these. At this time, the components may be included in the residual amount excluding the by-product of the extraction process based on the total weight of the food composition for anti-inflammatory according to the present invention.

The composition according to an embodiment of the present invention may be a feed composition for anti-inflammatory.

At this time, the anti-inflammatory feed composition may be formulated in a solid state formulation, for example, powder, pills (granule), tablets, and the like.

For example, the anti-inflammatory feed composition according to the present invention may be formulated in a powder form containing 35 to 50% by weight of the extraction and processing by-products according to the present invention, based on the total weight of the composition.

For example, the anti-inflammatory feed composition according to the present invention may be formulated as a pill containing 35 to 50% by weight of the extract by-product according to the present invention, based on the total weight of the composition.

For example, the anti-inflammatory feed composition according to the present invention may be formulated as a tablet containing 70 to 95% by weight of the extract by-product according to the present invention, based on the total weight of the composition.

In addition, it may further include feed additives commonly used in the art for the desired formulation. For example, vegetable feed additives such as grains, root fruits, food processing by-products, algae, fiber, pharmaceutical by-products, fats and oils, starch, peels or grain by-products; And animal feed additives such as proteins, inorganics, oils and fats, oils and fats, single cell proteins or animal planktons, etc., and may be formulated using one or a mixture of two or more of them. At this time, the feed additive may be included as a residual amount excluding the by-product of the extraction process based on the total weight of the anti-inflammatory feed composition according to the present invention.

Also, since the by-product of the extraction process according to the present invention has no problem in terms of safety, it can be used in an amount of the above range if necessary.

 Hereinafter, preferred embodiments are provided to help understanding of the present invention. However, the following examples are provided only for easier understanding of the present invention, and the following examples are merely illustrative and are not intended to limit the scope of the present invention in any way.

(Assessment Methods)

To measure anti-inflammatory efficacy, expression levels of inflammation-causing cytokines (IL-1β, IL-6, TNF-α) were measured from the blood of acute inflammation-induced mice.

Specifically, in order to measure the anti-inflammatory efficacy, BALB / c mice were used for experiments when the mice were 6 weeks of age after 1 week of stabilization. The normal group (no treatment) and the control group (control) for administering only distilled water, the experimental group for administering the compositions of Examples or Comparative Examples at 200 and 400 (mg / kg / day), respectively, were divided into a total of four groups each day 1 Times, 200 µl at 2 pm was administered orally for 7 days using an oral zonde, and a free diet was supplied during the experiment. After 7 days of oral administration, 1 mg / kg of lipid polysaccharide (LPS) was injected into the abdominal cavity, followed by anesthesia with ethyl ether 90 minutes later, and blood was collected by cardiac puncture. At this time, the dosage of the sample was calculated based on the intake amount once per 60 kg of adult body weight and the sample obtained from the intake amount based on 30 g of mouse body weight.

After the end of the experiment, blood collected using cardiac puncture was cured at room temperature (23 ° C.) for 30 minutes, and then centrifuged at 3,000 rpm for 15 minutes to separate serum. Expression levels of inflammation-inducing cytokines (IL-1β, IL-6, TNF-α) with separated serum were measured using Luminex. In addition, the measured experimental results were statistically processed using unpairedstudent's T-test and ANOVA of SPSS 11.0, and the significance was tested at p <0.05, p <0.01 and p <0.001 levels.

(Example 1)

The washed chicken feet (10 kg) were put in a hot water pot and autoclaved for 15 minutes by applying a pressure of 2 atmospheres to a temperature of 121 ° C., and then 15 kg of distilled water was put in a hot water pot and boiled at a temperature of 100 ° C. for 24 hours. Then, distilled water was distilled under a reduced pressure concentration process at a temperature of 60 ° C. to obtain chicken foot extract (5 kg).

350 g of the obtained chicken foot extract was added to 2.5 kg of distilled water heated to a temperature of 60 ° C. After the temperature of the contents was lowered to 40 ° C., 150 g of dandelion, 200 g of safflower seed, 150 g of hyssop and 150 g of mixed roots were simultaneously added, stirred uniformly for 30 minutes, and then freeze-dried by a conventional method to obtain brown powder. Obtained (650 g). At this time, the powder of 200 mesh (average particle size 1,270 nm) was used for each herbal ingredient. See Table 1 below for the amount of each component used.

Using the obtained composition, anti-inflammatory efficacy was measured according to the above evaluation method.

(Example 2)

Each component was prepared and added according to the method of Example 1 in the amount shown in Table 1, followed by lyophilization to obtain a brown powder (600 g). At this time, N-acetyl glucosamine was added at the same time when the mixed herbal medicines were added.

Using the obtained composition, anti-inflammatory efficacy was measured according to the above evaluation method.

(Examples 3 to 6)

Each component was prepared and added according to the method of Example 1 in the amount shown in Table 1, followed by lyophilization to obtain a brown powder (600 g).

Using the obtained composition, anti-inflammatory efficacy was measured according to the evaluation method. Anti-inflammatory efficacy was also measured according to the evaluation method.

(Comparative Examples 1 to 3)

Each component was prepared and added according to the method of Example 1 in the amount shown in Table 1, followed by lyophilization (600 g). However, the composition obtained in each comparative example was not in powder form but in a wet gel form.

Using the obtained composition, anti-inflammatory efficacy was measured according to the above evaluation method.

(Formulation Example 1)

35g of the composition of Example 2, 35g of rice bran, 10g of seaweed calcium, 10g of dietary sulfur (Methylsulfonylmethane, MSM) and 10g of vitamin C were mixed, molded into granules using a fluidized bed granulator, and then filled into a fabric to prepare pills.

(Formulation Example 2)

85 g of the composition of Example 2, 10 g of rice bran and 5 g of seaweed calcium were mixed, granulated using a fluidized bed dryer, and 6 mg of sugar ester was added thereto, followed by tableting with a tableting machine to prepare tablets.

As shown in Figure 1 below, in the group orally administered Example 2 of the present invention at 200 or 400 (mg / kg / day), interleukin at 132.27 ± 17.34 pg / ml, 120.51 ± 24.4 pg / ml, respectively. It was confirmed that the expression level of 1 beta (IL-1β) can be significantly suppressed. In addition, in the group to which Example 2 of the present invention was orally administered, it was confirmed that the expression level of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) also showed remarkable inhibitory ability, and the effect thereof was concentration. It was confirmed that it showed an inhibitory effect on expression level dependently (see FIGS. 2 and 3).

These results correspond to a decrease in significance (***: p <0.001) compared to a control in all examples according to the present invention. Specifically, the anti-inflammatory effect of Example 2 described above is Example 1 and Example The same amount used in 2 N-acetylglucosamine It corresponds to a remarkable level compared to the anti-inflammatory effect alone.

On the other hand, in the comparative example, the effect of suppressing expression on the above-described inflammation-inducing cytokine was minimal. In addition, in the case of Comparative Examples 1 to 3, the obtained composition showed a wet gel form, and of course, caused rapid rancidity (deterioration or decay).

As described above, the composition according to the present invention has an anti-inflammatory effect, that is, an effect of suppressing the expression of inflammation-inducing cytokines is excellent, and it is expected that it can be used as a formulation for inflammatory disease-related forms of various aspects as it can maintain stable quality for a long time. do.

The specific parts of the present invention have been described in detail above, and it is clear that for those skilled in the art, these specific technologies are merely examples, and the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims (3)

In the manufacturing method of the anti-inflammatory composition comprising the herbal,
The method for preparing the anti-inflammatory composition is to introduce a mixed medicinal herb containing dandelion, safflower seeds, hyssop and brown roots in chicken foot extract,
Based on the total weight of the composition, 20 to 35% by weight of chicken feet extract and 55 to 75% by weight of mixed herbal medicine, and 5 to 15% by weight of a glucosamine-based compound containing N-acetyl glucosamine,
The method for preparing an anti-inflammatory composition, wherein the mixed herbal medicine satisfies the following relationship:
[Relationship 1]
0.85 ≤ A + B / C + D ≤ 1.2
[In the above equation 1,
A (dandelion), B (safflower seed), C (wooss) and D (grass root) are the weight percent of each herbal medicine in powder form having an average particle diameter of 300 to 1,500 nm, and the weight percent of each herbal medicine is based on the total weight of the composition Let's do it.]
According to claim 1,
The method for preparing an anti-inflammatory composition is a method for preparing an anti-inflammatory composition, characterized in that the food composition for anti-inflammatory is prepared.
According to claim 1,
The method for preparing the anti-inflammatory composition is a method for preparing the anti-inflammatory composition, characterized in that for preparing the anti-inflammatory feed composition

Images